Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On May 10, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the first quarter of 2024 and provided a business update.</li><li>The company announced that the Phase 2 clinical trial of IMC-2 (valacycovir+celecoxib) has reached 50% enrollment and we anticipate topline results from the trial in the second half of 2024.</li><li>Earlier this year, Virios announced that it had reached alignment with the U.S. Food and Drug Administration (FDA) that would allow the company to use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint in future trials of IMC-2 for the treatment of Long COVID. The results of the ongoing Phase 2 trial of IMC-2 will help to guide the final design of a Phase 2b trial.</li></ul>

On May 10, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the first quarter of 2024 and provided a business update.The company announced that the Phase 2 clinical trial of IMC-2 (valacycovir+celecoxib) has reached 50% enrollment and we anticipate topline results from the trial in the second half of 2024.Earlier this year, Virios announced that it had reached alignment with the U.S. Food and Drug Administration (FDA) that would allow the company to use fatigue as the primary endpoint and orthostatic intolerance as a key secondary endpoint in future trials of IMC-2 for the treatment of Long COVID. The results of the ongoing Phase 2 trial of IMC-2 will help to guide the final design of a Phase 2b trial.

VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24 

United States

Dogwood Therapeutics, Inc. operates as a development-stage biotechnology. The Company develops novel therapeutics and sodium channel blocker to treat moderate-to-severe chemotherapy induced neuropathic pain, cancer pain, and other pain indications. Dogwood Therapeutics serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dogwood Therapeutics (DWTX US)

VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24

On May 10, 2024, Virios Therapeutics, Inc. (VIRI) announced financial results for the first quarter of 2024 and provided a business update. The...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)